These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39188100)

  • 21. FOLFIRINOX for Advanced Pancreatic Cancer Patients After Nab-Paclitaxel Plus Gemcitabine Failure.
    Matsumoto T; Kurioka Y; Okazaki U; Matsuo Y; Kimura S; Miura K; Tsuduki T; Takagi S; Takatani M; Morishita H
    Pancreas; 2020 Apr; 49(4):574-578. PubMed ID: 32282772
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment landscape of metastatic pancreatic cancer.
    De Dosso S; Siebenhüner AR; Winder T; Meisel A; Fritsch R; Astaras C; Szturz P; Borner M
    Cancer Treat Rev; 2021 May; 96():102180. PubMed ID: 33812339
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sustained response with gemcitabine plus Nab-paclitaxel after folfirinox failure in metastatic pancreatic cancer: report of an effective new strategy.
    Portal A; Pernot S; Siauve N; Landi B; Lepère C; Colussi O; Rougier P; Zaanan A; Verrière B; Taieb J
    Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):e23-6. PubMed ID: 24559766
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Response in
    Campoverde LE; Batalini F; Bulushi Y; Bullock A
    BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35487638
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pancreatic acinar cell carcinoma with bilateral ovarian metastases, panniculitis and polyarthritis treated with FOLFIRINOX chemotherapy regimen. A case report and review of the literature.
    Callata-Carhuapoma HR; Pato Cour E; Garcia-Paredes B; Fernandez RM; Mendoza Fernandez ML; Fernandez AM; De La Rosa CA; Sotelo Lezama MJ; Cabezas-Camarero S; Sastre Varela J
    Pancreatology; 2015; 15(4):440-4. PubMed ID: 25959244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy susceptible germline-related BRCA 1-mutation in a case of metastasized mixed adeno-neuroendocrine carcinoma (MANEC) of the small bowel.
    Quaas A; Waldschmidt D; Alakus H; Zander T; Heydt C; Goeser T; Daheim M; Kasper P; Plum P; Bruns C; Brunn A; Roth W; Hartmann N; Bunck A; Schmidt M; Göbel H; Tharun L; Buettner R; Merkelbach-Bruse S
    BMC Gastroenterol; 2018 May; 18(1):75. PubMed ID: 29855275
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    Shimmura H; Kuramochi H; Jibiki N; Katagiri S; Nishino T; Araida T
    Jpn J Clin Oncol; 2019 Dec; 49(11):1049-1054. PubMed ID: 31612916
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical Outcomes of S-1 Monotherapy and Modified FOLFIRINOX Therapy after Gemcitabine plus Nab-paclitaxel Therapy in Unresectable Pancreatic Cancer.
    Hino K; Nishina T; Numata Y; Asagi A; Inoue T; Yoshimatsu M; Sakaguchi C; Nakasya A; Nishide N; Kajiwara T; Terao T; Nadano S; Marui K; Okujima Y; Kokubu M; Imamura Y; Kanemitsu K; Koizumi M; Kumagi T; Hiasa Y; Hyodo I
    Intern Med; 2022; 61(15):2255-2261. PubMed ID: 35908959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival Outcomes Based on Sequence of Therapy Using FOLFIRINOX and Nab-Paclitaxel + Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma.
    Baron MK; Wang X; Nevala-Plagemann C; Moser JC; Haaland B; Garrido-Laguna I
    Pancreas; 2021 Jul; 50(6):796-802. PubMed ID: 34347727
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA
    Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective comparative study of S-IROX and modified FOLFIRINOX for patients with advanced pancreatic cancer refractory to gemcitabine plus nab-paclitaxel.
    Saito K; Nakai Y; Takahara N; Ishigaki K; Suzuki Y; Inokuma A; Noguchi K; Kanai S; Sato T; Hakuta R; Saito T; Hamada T; Mizuno S; Kogure H; Ijichi H; Tateishi K; Koike K
    Invest New Drugs; 2021 Apr; 39(2):605-613. PubMed ID: 33094362
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanoliposomal irinotecan with fluorouracil and folinic acid, FOLFIRINOX, and S-1 as second-line treatment for unresectable pancreatic cancer after gemcitabine/nab-paclitaxel.
    Shibuki T; Otsuka T; Shimokawa M; Nakazawa J; Arima S; Fukahori M; Miwa K; Okabe Y; Koga F; Ueda Y; Kubotsu Y; Makiyama A; Shimokawa H; Takeshita S; Nishikawa K; Komori A; Otsu S; Hosokawa A; Sakai T; Oda H; Kawahira M; Arita S; Honda T; Taguchi H; Tsuneyoshi K; Kawaguchi Y; Fujita T; Sakae T; Nio K; Ide Y; Ureshino N; Shirakawa T; Mizuta T; Mitsugi K
    Sci Rep; 2024 Jul; 14(1):16906. PubMed ID: 39043707
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of germline breast cancer susceptibility gene (gBRCA) testing and olaparib as maintenance therapy for patients with pancreatic cancer.
    Kawamoto Y; Yamai T; Ikezawa K; Seiki Y; Watsuji K; Hirao T; Urabe M; Kai Y; Takada R; Mukai K; Nakabori T; Uehara H; Inoue T; Fujisawa F; Ohkawa K
    BMC Cancer; 2024 Aug; 24(1):1000. PubMed ID: 39134950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Gemcitabine plus nab-paclitaxel vs. FOLFIRINOX for patients with advanced pancreatic cancer.
    Tahara J; Shimizu K; Otsuka N; Akao J; Takayama Y; Tokushige K
    Cancer Chemother Pharmacol; 2018 Aug; 82(2):245-250. PubMed ID: 29846765
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection.
    Wolfe AR; Prabhakar D; Yildiz VO; Cloyd JM; Dillhoff M; Abushahin L; Alexandra Diaz D; Miller ED; Chen W; Frankel WL; Noonan A; Williams TM
    Cancer Med; 2020 Jul; 9(13):4711-4723. PubMed ID: 32415696
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Statewide Retrospective Review of Familial Pancreatic Cancer in Delaware, and Frequency of Genetic Mutations in Pancreatic Cancer Kindreds.
    Catts ZA; Baig MK; Milewski B; Keywan C; Guarino M; Petrelli N
    Ann Surg Oncol; 2016 May; 23(5):1729-35. PubMed ID: 26727920
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Surgical resection of hepatic and rectal metastases of pancreatic acinar cell carcinoma (PACC): a case report.
    Ohara Y; Oda T; Enomoto T; Hisakura K; Akashi Y; Ogawa K; Owada Y; Domoto Y; Miyazaki Y; Shimomura O; Kurata M; Ohkohchi N
    World J Surg Oncol; 2018 Aug; 16(1):158. PubMed ID: 30075727
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Meta-analysis and indirect treatment comparison of modified FOLFIRINOX and gemcitabine plus nab-paclitaxel as first-line chemotherapy in advanced pancreatic cancer.
    Chen J; Hua Q; Wang H; Zhang D; Zhao L; Yu D; Pi G; Zhang T; Lin Z
    BMC Cancer; 2021 Jul; 21(1):853. PubMed ID: 34301232
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparisons of Outcomes of Real-World Patients With Advanced Pancreatic Cancer Treated With FOLFIRINOX Versus Gemcitabine and Nab-Paclitaxel: A Population-Based Cohort Study.
    Papneja N; Zaidi A; Chalchal H; Moser M; Tan K; Olson C; Haider K; Shaw J; Ahmed S
    Pancreas; 2019 Aug; 48(7):920-926. PubMed ID: 31180981
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.